The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Top Cited Papers
- 10 July 2012
- journal article
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 30 (7), 631-637
- https://doi.org/10.1038/nbt.2289
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Current approaches and future directions in the treatment of HER2-positive breast cancerCancer Treatment Reviews, 2013
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II StudyJournal of Clinical Oncology, 2012
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesNature Biotechnology, 2012
- SG2285, a Novel C2-Aryl-Substituted Pyrrolobenzodiazepine Dimer Prodrug That Cross-links DNA and Exerts Highly Potent Antitumor ActivityCancer Research, 2010
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast CancerJournal of Clinical Oncology, 2010
- Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tagProceedings of the National Academy of Sciences of the United States of America, 2009
- Anti-CD30 diabody-drug conjugates with potent antitumor activityMolecular Cancer Therapeutics, 2008
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexNature Biotechnology, 2008
- Combination of the anti‐CD30‐auristatin‐E antibody‐drug conjugate (SGN‐35) with chemotherapy improves antitumour activity in Hodgkin lymphomaBritish Journal of Haematology, 2008